Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

334 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Antisense therapy against CCR3 and the common beta chain attenuates allergen-induced eosinophilic responses.
Gauvreau GM, Boulet LP, Cockcroft DW, Baatjes A, Cote J, Deschesnes F, Davis B, Strinich T, Howie K, Duong M, Watson RM, Renzi PM, O'Byrne PM. Gauvreau GM, et al. Among authors: cockcroft dw. Am J Respir Crit Care Med. 2008 May 1;177(9):952-8. doi: 10.1164/rccm.200708-1251OC. Epub 2008 Jan 31. Am J Respir Crit Care Med. 2008. PMID: 18244953 Clinical Trial.
Prolonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting beta(2)-agonist, in patients with mild asthma.
O'Byrne PM, van der Linde J, Cockcroft DW, Gauvreau GM, Brannan JD, Fitzgerald M, Watson RM, Milot J, Davis B, O'Connor M, Hart L, Korducki L, Hamilton AL, Boulet LP. O'Byrne PM, et al. Among authors: cockcroft dw. J Allergy Clin Immunol. 2009 Dec;124(6):1217-21. doi: 10.1016/j.jaci.2009.08.047. J Allergy Clin Immunol. 2009. PMID: 20004781 Clinical Trial.
A nonsteroidal glucocorticoid receptor agonist inhibits allergen-induced late asthmatic responses.
Gauvreau GM, Boulet LP, Leigh R, Cockcroft DW, Killian KJ, Davis BE, Deschesnes F, Watson RM, Swystun V, Mårdh CK, Wessman P, Jorup C, Aurivillius M, O'Byrne PM. Gauvreau GM, et al. Among authors: cockcroft dw. Am J Respir Crit Care Med. 2015 Jan 15;191(2):161-7. doi: 10.1164/rccm.201404-0623OC. Am J Respir Crit Care Med. 2015. PMID: 25473939 Clinical Trial.
Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses.
Gauvreau GM, Arm JP, Boulet LP, Leigh R, Cockcroft DW, Davis BE, Mayers I, FitzGerald JM, Dahlen B, Killian KJ, Laviolette M, Carlsten C, Lazarinis N, Watson RM, Milot J, Swystun V, Bowen M, Hui L, Lantz AS, Meiser K, Maahs S, Lowe PJ, Skerjanec A, Drollmann A, O'Byrne PM. Gauvreau GM, et al. Among authors: cockcroft dw. J Allergy Clin Immunol. 2016 Oct;138(4):1051-1059. doi: 10.1016/j.jaci.2016.02.027. Epub 2016 Apr 7. J Allergy Clin Immunol. 2016. PMID: 27185571 Clinical Trial.
Effect of Sch1000 in allergen-induced asthma.
Cockcroft DW, Ruffin RE, Hargreave FE. Cockcroft DW, et al. Clin Allergy. 1978 Jul;8(4):361-72. doi: 10.1111/j.1365-2222.1978.tb00471.x. Clin Allergy. 1978. PMID: 152170
334 results